Highlights

• Metabolic syndrome is a serious health condition that affects about 23% of adults in the United States, putting them at higher risk of cardiovascular disease, diabetes mellitus, stroke, and diseases related to buildup of fatty plaque in artery walls.

• Diabetes mellitus is a group of metabolic diseases that increase the risk of microvascular and macrovascular complications.

• Teprotumumab, an investigational drug, may slow progression of ophthalmopathy in patients with moderate to severe thyroid eye disease.

Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.